The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: Human AFG3L2 (UniProt Q9Y4W6) — Functional Annotation and Disease Relevance

Executive summary

AFG3L2 (UniProt Q9Y4W6) encodes a mitochondrial inner membrane (IMM) m-AAA protease subunit that assembles as homo-hexamers or hetero-hexamers with SPG7/paraplegin. The complex performs ATP-dependent, zinc-metalloprotease proteolysis (protein quality control and regulatory processing) with catalytic sites facing the mitochondrial matrix. Recent 2023–2024 literature substantially expanded the experimentally supported substrate set (e.g., SLC25A39 for glutathione homeostasis; MRPL32/bL32m for mitoribosome assembly; EMRE for mitochondrial Ca2+ regulation) and connected AFG3L2 activity to cell-state regulation, including hypoxia signaling via HIF1α–mTORC1 and stress signaling via OMA1–DELE1–HRI integrated stress response (ISR). Pathogenic variants cause a spectrum from dominant SCA28 and dominant optic atrophy 12 (DOA12/OPA12) to recessive early-onset SPAX5, with emerging preclinical therapeutic strategies centered on ISR tuning (e.g., Sephin-1) in SPAX5 models. (franchino2024sustainedoma1mediatedintegrated pages 1-2, dastidar2024multifacetedrolesof pages 1-2, liu2023autoregulatorycontrolof pages 3-4, chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13)

1) Gene/protein identity verification (mandatory)

The gene symbol AFG3L2 in the recent literature matches the UniProt-defined target Q9Y4W6: a mitochondrial inner membrane m-AAA protease component with AAA+ ATPase and zinc metalloprotease activities, assembling into m-AAA protease complexes (homo-oligomeric AFG3L2 or hetero-oligomeric AFG3L2–SPG7). These defining characteristics are repeatedly stated in 2023–2024 review and primary sources. (franchino2024sustainedoma1mediatedintegrated pages 1-2, dastidar2024multifacetedrolesof pages 1-2, dastidar2024multifacetedrolesof pages 2-5, khalimonchuk2023moleculardeterminantsof pages 6-8)

2) Key concepts and definitions (current understanding)

2.1 m-AAA protease and mitochondrial proteostasis

m-AAA proteases are IMM-embedded ATP-dependent protease complexes that provide protein quality control (PQC) by selective removal/processing of non-assembled or damaged mitochondrial proteins, thereby supporting inner membrane integrity and organelle function. AFG3L2-containing m-AAA is explicitly described as a core component of IMM quality control mediating selective degradation. (franchino2024sustainedoma1mediatedintegrated pages 1-2)

2.2 Domain logic and catalytic mechanism (AAA+ ATPase + Zn metalloprotease)

AFG3L2 is functionally defined by:
- an AAA+ ATPase module that uses ATP hydrolysis to engage, unfold, and translocate substrates through the central pore of the hexamer; and
- a C-terminal zinc metalloprotease domain that cleaves substrates after translocation.

A 2024 review describes ATP-stabilized hexamer assembly and a mechanistic sequence: substrate recruitment, ATP-dependent pore-loop engagement/translocation, followed by cleavage at a Zn-associated protease site. (dastidar2024multifacetedrolesof pages 1-2, dastidar2024multifacetedrolesof pages 2-5)

2.3 Subcellular localization and topology

AFG3L2 localizes to the mitochondrial inner membrane with catalytic faces oriented to the matrix (matrix-facing AAA+ and proteolytic sites). (franchino2024sustainedoma1mediatedintegrated pages 1-2, khalimonchuk2023moleculardeterminantsof pages 6-8, chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5)

3) Primary molecular function: reaction, substrate specificity, and pathways

3.1 Primary biochemical function

AFG3L2’s primary function is ATP-dependent proteolysis (metalloprotease EC 3.4.24.- class in UniProt terms) of specific mitochondrial substrates and misfolded/damaged IMM-associated proteins, coupled to ATP-dependent unfolding/translocation by its AAA+ motor. This is not a passive “housekeeping” role: multiple studies support regulatory substrate processing/degradation that tunes mitochondrial metabolism, Ca2+ transport, and gene expression. (franchino2024sustainedoma1mediatedintegrated pages 1-2, dastidar2024multifacetedrolesof pages 2-5, chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5)

3.2 Experimentally supported substrates (high-confidence examples)

3.2.1 SLC25A39 (mitochondrial glutathione transporter) — metabolic feedback control (2023)

A 2023 Science paper establishes a direct functional axis in which AFG3L2 degrades SLC25A39 under physiological conditions. Key quantitative data:
- SLC25A39 has an estimated half-life of ~15 minutes at baseline.
- Mitochondrial glutathione (GSH) depletion stabilizes SLC25A39 to >300 minutes.
- Glutathione supplementation restores rapid degradation.
A CRISPR screen of mitochondrial peptidases identified AFG3L2 as the only significant hit controlling this regulation, supporting substrate specificity and a compartmentalized feedback loop for mitochondrial GSH homeostasis. (liu2023autoregulatorycontrolof pages 3-4)

3.2.2 MRPL32 / bL32m (mitoribosome biogenesis)

Recent sources describe m-AAA/AFG3L2 as supporting mitochondrial ribosome assembly via processing/biogenesis of the ribosomal subunit bL32m (MRPL32). (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5, khalimonchuk2023moleculardeterminantsof pages 6-8)

3.2.3 EMRE (MCU regulator) — mitochondrial Ca2+ handling

AFG3L2/m-AAA is connected to maturation/turnover of EMRE, a regulatory component of the mitochondrial calcium uniporter. This links AFG3L2 proteolysis to mitochondrial Ca2+ uptake control. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5, khalimonchuk2023moleculardeterminantsof pages 6-8)

3.2.4 TIMMDC1 (Complex I assembly factor)

A 2024 preprint reports TIMMDC1 as an AFG3L2 substrate whose degradation links AFG3L2 to complex I assembly control and OXPHOS remodeling. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5, chandragiri2024afg3l2mediatedproteolysisrestricts pages 5-9)

3.2.5 TMBIM5/GHITM (Ca2+/H+ homeostasis; inhibitor-substrate duality)

In hypoxia-linked remodeling, TMBIM5 (GHITM) is described as both a substrate and an inhibitor/modulator of AFG3L2, implying feedback regulation that connects protease activity to mitochondrial ion homeostasis. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 13-16)

3.2.6 Expanded substrate landscape in hypoxia: RNA metabolism and biogenesis factors (2024)

Proteomic evidence under hypoxia suggests AFG3L2 targets numerous factors involved in mitochondrial gene expression and RNA granules, including LRPPRC, SLIRP, MTPAP, POLRMT, TFB2M, DHX30, GRSF1, as well as import factors (PAM16, DNAJC15, TIMM17A). These data support a model where AFG3L2 proteolysis can restrict mitochondrial biogenesis and gene expression under defined signaling conditions rather than only clearing misfolded proteins. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 13-16)

4) Recent developments and latest research (prioritize 2023–2024)

4.1 2023: AFG3L2 couples glutathione availability to transporter turnover

The Liu et al. (Science, Nov 2023) study is a major mechanistic advance: it defines a concrete, quantitative, metabolite-coupled protease–transporter feedback loop in mitochondria, where GSH levels gate AFG3L2-mediated degradation of SLC25A39. This provides a molecular explanation for how mitochondria can regulate a key metabolite transporter post-translationally. Publication date: Nov 2023. URL: https://doi.org/10.1126/science.adf4154 (liu2023autoregulatorycontrolof pages 3-4)

4.2 2024: Disease mechanism and therapy concept in SPAX5 — ISR as protective output

Franchino et al. (Brain, Oct 2024) connect AFG3L2 deficiency to:
- accumulation of mitochondria-encoded proteins and mitochondrial proteotoxicity,
- OMA1 overactivation with OPA1 over-processing and mitochondrial fragmentation, and
- activation of the OMA1–DELE1–HRI ISR (elevated eIF2α phosphorylation; increased ATF4; upregulation of targets including Chop, Chac1, Ppp1r15a, Fgf21).

Importantly, they show pharmacologic potentiation of ISR via Sephin-1 improves growth of SPAX5 fibroblasts, improves Purkinje neuron survival/arborization ex vivo, and extends lifespan and improves cerebellar/mitochondrial phenotypes in Afg3l2−/− mice—supporting ISR modulation as a plausible therapeutic direction. Publication date: Oct 2024. URL: https://doi.org/10.1093/brain/awad340 (franchino2024sustainedoma1mediatedintegrated pages 1-2)

4.3 2024: Hypoxia signaling connects AFG3L2 to control of mitochondrial biogenesis and gene expression

A 2024 preprint reports that AFG3L2 proteolysis is activated in hypoxia along a HIF1α–mTORC1 axis; regulation is primarily post-translational (activity changes without requiring increased AFG3L2 abundance). Quantitative scope: proteomics suggests dozens of candidate substrates, including 38 proteins reduced with amino-acid starvation and 72 proteins decreased in hypoxia in an AFG3L2-dependent manner. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13)

This work further positions AFG3L2 as a regulated node in mitochondrial remodeling rather than a purely constitutive PQC enzyme. Publication date: Sep 2024 (bioRxiv). URL: https://doi.org/10.1101/2024.09.27.615438 (chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13)

5) Current applications and real-world implementations

5.1 Clinical genetics and diagnostics

AFG3L2 is implemented clinically primarily through molecular genetic testing for hereditary ataxia and optic neuropathy. A 2024 diagnostic classification review notes that for SCA28, >99% of reported cases are due to SNVs or small intragenic deletions/insertions (with copy-number changes reported as extremely rare), guiding practical test selection (sequencing prioritized; CNV assessment secondary). (lopergolo2024autosomalrecessivecerebellar pages 4-5)

Reviews emphasize that multigene panels and/or clinical exome sequencing support diagnosis, particularly when common ataxia causes are excluded. (dastidar2024multifacetedrolesof pages 15-16, dastidar2024multifacetedrolesof pages 10-11)

5.2 Preclinical therapeutic strategies with translational logic

• ISR tuning as therapy (SPAX5): Sephin-1 improved multiple cellular and organismal endpoints in Afg3l2 deficiency models, providing a concrete lead for future translational development and defining potential pharmacodynamic biomarkers (eIF2α phosphorylation; ATF4 targets). (franchino2024sustainedoma1mediatedintegrated pages 1-2)
• Supportive care remains standard for SCA28: reviews indicate no disease-modifying therapy currently; management is supportive and rehabilitative. (dastidar2024multifacetedrolesof pages 15-16)

5.3 Biomarkers and mechanistic readouts

A 2024 Brain study provides a coherent biomarker axis in patient fibroblasts and mouse cerebellum: increased eIF2α phosphorylation, ATF4, and downstream targets including CHOP/CHAC1/PPP1R15A/FGF21 in SPAX5 contexts. These may serve as candidate biomarkers for patient stratification or monitoring in future interventions targeting the ISR. (franchino2024sustainedoma1mediatedintegrated pages 1-2)

6) Human phenotypes and genotype–phenotype mapping (current 2024 view)

6.1 Dominant SCA28 (MIM#610246)

SCA28 is described as a slowly progressive cerebellar ataxia, typically with oculomotor abnormalities; heterozygous pathogenic variants are a primary genetic cause. (dastidar2024multifacetedrolesof pages 15-16, franchino2024sustainedoma1mediatedintegrated pages 1-2)

6.2 Dominant optic neuropathy: DOA12/OPA12 (MIM#618977)

Heterozygous variants (notably in ATPase/catalytic domains) are linked to dominant optic atrophy 12, and may overlap with additional ocular/mitochondrial phenotypes depending on variant and genetic context. (dastidar2024multifacetedrolesof pages 15-16, franchino2024sustainedoma1mediatedintegrated pages 1-2)

6.3 Recessive early-onset spastic ataxia-neuropathy: SPAX5 / spastic ataxia type 5

Biallelic loss-of-function variants cause a severe childhood-onset neurodegenerative disorder including cerebellar ataxia, spasticity, dystonia, neuropathy, and potentially myoclonic epilepsy. (dastidar2024multifacetedrolesof pages 15-16, franchino2024sustainedoma1mediatedintegrated pages 1-2)

7) Expert opinion / analysis (authoritative perspectives grounded in evidence)

1. AFG3L2 is increasingly viewed as a regulated remodeling protease, not merely a constitutive “garbage disposal.” Evidence includes stress- and nutrient-state regulation (HIF1α–mTORC1 axis) with broad substrate turnover shifts under hypoxia. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13)
2. Distinct mechanistic “modules” connect AFG3L2 dysfunction to disease:
3. proteotoxic stress → OMA1 activation → OPA1 processing → mitochondrial fragmentation → ISR activation, with ISR shown to be beneficial when pharmacologically potentiated in SPAX5 models. (franchino2024sustainedoma1mediatedintegrated pages 1-2)
4. metabolite sensing/feedback → GSH-dependent control of SLC25A39 abundance, linking AFG3L2 to redox and Fe–S-linked metabolism. (liu2023autoregulatorycontrolof pages 3-4)

Together these suggest that therapeutic strategies may need to be tailored to the dominant mechanistic axis in a given genotype/phenotype (e.g., ISR modulation for SPAX5-like biallelic loss; metabolic/proteostasis stabilization approaches for other contexts). (liu2023autoregulatorycontrolof pages 3-4, franchino2024sustainedoma1mediatedintegrated pages 1-2)

8) Relevant statistics and quantitative data (from recent studies)

• SLC25A39 protein half-life: ~15 min at baseline; stabilized to >300 min under mitochondrial GSH depletion (MitoCHAC1 strategy) and rapidly degraded upon GSH supplementation, implicating AFG3L2-mediated control. (Nov 2023; https://doi.org/10.1126/science.adf4154) (liu2023autoregulatorycontrolof pages 3-4)
• Scale of AFG3L2-dependent proteome remodeling in hypoxia: proteomics reported 38 proteins reduced with amino-acid starvation and 72 proteins decreased in hypoxia in an AFG3L2-dependent manner, emphasizing broad but enriched targeting of mitochondrial gene-expression machinery and related pathways. (Sep 2024; https://doi.org/10.1101/2024.09.27.615438) (chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13)
• Genetic variant-type distribution for SCA28: a 2024 diagnostic review table reports >99% of reported SCA28 cases involve SNVs/small intragenic indels, with monoallelic deletion/duplication described as extremely rare, informing testing strategy. (Feb 2024; https://doi.org/10.3389/fnint.2023.1275794) (lopergolo2024autosomalrecessivecerebellar pages 4-5)

9) Evidence map (structured summary)

The following table consolidates the main functional and translational points (complex identity, substrates, regulation, diseases) with DOI URLs.

Table: This table condenses the core functional annotation of human AFG3L2, including complex identity, localization, catalytic mechanism, experimentally supported substrates, regulatory pathways, and associated human diseases. It is useful as a quick-reference map linking molecular function to disease relevance and recent literature.

10) Limitations of the current evidence base (important for annotation quality)

• Some mechanistic claims in the 2024 hypoxia study are from a bioRxiv preprint and therefore not yet peer-reviewed; the results are still useful as “latest research” but should be treated cautiously until validated. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5, chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13)
• AFG3L2-disease epidemiology (penetrance, population prevalence of SCA28/DOA12/SPAX5 specifically) was not directly available in the retrieved 2023–2024 sources; the report therefore focuses on mechanistic and diagnostic implementation evidence rather than attempting unsupported prevalence estimates. (dastidar2024multifacetedrolesof pages 15-16, lopergolo2024autosomalrecessivecerebellar pages 4-5)

Key recent sources (URLs + publication timing)

• Liu et al., Science, Nov 2023: https://doi.org/10.1126/science.adf4154 (liu2023autoregulatorycontrolof pages 3-4)
• Khalimonchuk & Becker, Antioxidants & Redox Signaling, May 2023: https://doi.org/10.1089/ars.2022.0124 (khalimonchuk2023moleculardeterminantsof pages 6-8)
• Franchino et al., Brain, Oct 2024: https://doi.org/10.1093/brain/awad340 (franchino2024sustainedoma1mediatedintegrated pages 1-2)
• Dastidar et al., Molecular Neurobiology, 2024 (online; issue cites Nov 2024): https://doi.org/10.1007/s12035-023-03768-z (dastidar2024multifacetedrolesof pages 1-2)
• Chandragiri et al., bioRxiv preprint, Sep 2024: https://doi.org/10.1101/2024.09.27.615438 (chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13)
• Lopergolo et al., Frontiers in Integrative Neuroscience, Feb 2024: https://doi.org/10.3389/fnint.2023.1275794 (lopergolo2024autosomalrecessivecerebellar pages 4-5)

References

1. (franchino2024sustainedoma1mediatedintegrated pages 1-2): Camilla Aurora Franchino, Martina Brughera, Valentina Baderna, Daniele De Ritis, Alessandra Rocco, Sara Seneca, Luc Regal, Paola Podini, Maurizio D’Antonio, Camilo Toro, Angelo Quattrini, Emmanuel Scalais, and Francesca Maltecca. Sustained oma1-mediated integrated stress response is beneficial for spastic ataxia type 5. Brain, 147:1043-1056, Oct 2024. URL: https://doi.org/10.1093/brain/awad340, doi:10.1093/brain/awad340. This article has 19 citations and is from a highest quality peer-reviewed journal.

2. (dastidar2024multifacetedrolesof pages 1-2): Ranita Ghosh Dastidar, Saradindu Banerjee, Piyush Behari Lal, and Somasish Ghosh Dastidar. Multifaceted roles of afg3l2, a mitochondrial atpase in relation to neurological disorders. Molecular Neurobiology, 61:3788-3808, Nov 2024. URL: https://doi.org/10.1007/s12035-023-03768-z, doi:10.1007/s12035-023-03768-z. This article has 19 citations and is from a peer-reviewed journal.

3. (liu2023autoregulatorycontrolof pages 3-4): Yuyang Liu, Shanshan Liu, Anju Tomar, Frederick S. Yen, Gokhan Unlu, Nathalie Ropek, Ross A. Weber, Ying Wang, Artem Khan, Mark Gad, Junhui Peng, Erdem Terzi, Hanan Alwaseem, Alexandra E. Pagano, Søren Heissel, Henrik Molina, Benjamin Allwein, Timothy C. Kenny, Richard L. Possemato, Li Zhao, Richard K. Hite, Ekaterina V. Vinogradova, Sheref S. Mansy, and Kıvanç Birsoy. Autoregulatory control of mitochondrial glutathione homeostasis. Nov 2023. URL: https://doi.org/10.1126/science.adf4154, doi:10.1126/science.adf4154. This article has 126 citations and is from a highest quality peer-reviewed journal.

4. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13): Srikanth Chandragiri, Nils Grotehans, Yvonne Lasarzewski, Maria Patron, Thomas MacVicar, Yohsuke Ohba, Steffen Hermans, Elena Rugarli, Hendrik Nolte, and Thomas Langer. Afg3l2-mediated proteolysis restricts mitochondrial biogenesis and gene expression in hypoxia. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.27.615438, doi:10.1101/2024.09.27.615438. This article has 2 citations.

5. (dastidar2024multifacetedrolesof pages 2-5): Ranita Ghosh Dastidar, Saradindu Banerjee, Piyush Behari Lal, and Somasish Ghosh Dastidar. Multifaceted roles of afg3l2, a mitochondrial atpase in relation to neurological disorders. Molecular Neurobiology, 61:3788-3808, Nov 2024. URL: https://doi.org/10.1007/s12035-023-03768-z, doi:10.1007/s12035-023-03768-z. This article has 19 citations and is from a peer-reviewed journal.

6. (khalimonchuk2023moleculardeterminantsof pages 6-8): Oleh Khalimonchuk and Donald F. Becker. Molecular determinants of mitochondrial shape and function and their role in glaucoma. Antioxidants & Redox Signaling, 38:896-919, May 2023. URL: https://doi.org/10.1089/ars.2022.0124, doi:10.1089/ars.2022.0124. This article has 7 citations and is from a domain leading peer-reviewed journal.

7. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5): Srikanth Chandragiri, Nils Grotehans, Yvonne Lasarzewski, Maria Patron, Thomas MacVicar, Yohsuke Ohba, Steffen Hermans, Elena Rugarli, Hendrik Nolte, and Thomas Langer. Afg3l2-mediated proteolysis restricts mitochondrial biogenesis and gene expression in hypoxia. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.27.615438, doi:10.1101/2024.09.27.615438. This article has 2 citations.

8. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 5-9): Srikanth Chandragiri, Nils Grotehans, Yvonne Lasarzewski, Maria Patron, Thomas MacVicar, Yohsuke Ohba, Steffen Hermans, Elena Rugarli, Hendrik Nolte, and Thomas Langer. Afg3l2-mediated proteolysis restricts mitochondrial biogenesis and gene expression in hypoxia. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.27.615438, doi:10.1101/2024.09.27.615438. This article has 2 citations.

9. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 13-16): Srikanth Chandragiri, Nils Grotehans, Yvonne Lasarzewski, Maria Patron, Thomas MacVicar, Yohsuke Ohba, Steffen Hermans, Elena Rugarli, Hendrik Nolte, and Thomas Langer. Afg3l2-mediated proteolysis restricts mitochondrial biogenesis and gene expression in hypoxia. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.27.615438, doi:10.1101/2024.09.27.615438. This article has 2 citations.

10. (lopergolo2024autosomalrecessivecerebellar pages 4-5): Diego Lopergolo, Francesca Rosini, Elena Pretegiani, Alessia Bargagli, Valeria Serchi, and Alessandra Rufa. Autosomal recessive cerebellar ataxias: a diagnostic classification approach according to ocular features. Frontiers in Integrative Neuroscience, Feb 2024. URL: https://doi.org/10.3389/fnint.2023.1275794, doi:10.3389/fnint.2023.1275794. This article has 10 citations.

11. (dastidar2024multifacetedrolesof pages 15-16): Ranita Ghosh Dastidar, Saradindu Banerjee, Piyush Behari Lal, and Somasish Ghosh Dastidar. Multifaceted roles of afg3l2, a mitochondrial atpase in relation to neurological disorders. Molecular Neurobiology, 61:3788-3808, Nov 2024. URL: https://doi.org/10.1007/s12035-023-03768-z, doi:10.1007/s12035-023-03768-z. This article has 19 citations and is from a peer-reviewed journal.

12. (dastidar2024multifacetedrolesof pages 10-11): Ranita Ghosh Dastidar, Saradindu Banerjee, Piyush Behari Lal, and Somasish Ghosh Dastidar. Multifaceted roles of afg3l2, a mitochondrial atpase in relation to neurological disorders. Molecular Neurobiology, 61:3788-3808, Nov 2024. URL: https://doi.org/10.1007/s12035-023-03768-z, doi:10.1007/s12035-023-03768-z. This article has 19 citations and is from a peer-reviewed journal.

13. (dastidar2024multifacetedrolesof pages 7-9): Ranita Ghosh Dastidar, Saradindu Banerjee, Piyush Behari Lal, and Somasish Ghosh Dastidar. Multifaceted roles of afg3l2, a mitochondrial atpase in relation to neurological disorders. Molecular Neurobiology, 61:3788-3808, Nov 2024. URL: https://doi.org/10.1007/s12035-023-03768-z, doi:10.1007/s12035-023-03768-z. This article has 19 citations and is from a peer-reviewed journal.

14. (dastidar2024multifacetedrolesof pages 13-15): Ranita Ghosh Dastidar, Saradindu Banerjee, Piyush Behari Lal, and Somasish Ghosh Dastidar. Multifaceted roles of afg3l2, a mitochondrial atpase in relation to neurological disorders. Molecular Neurobiology, 61:3788-3808, Nov 2024. URL: https://doi.org/10.1007/s12035-023-03768-z, doi:10.1007/s12035-023-03768-z. This article has 19 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Citations

1. liu2023autoregulatorycontrolof pages 3-4
2. lopergolo2024autosomalrecessivecerebellar pages 4-5
3. dastidar2024multifacetedrolesof pages 15-16
4. khalimonchuk2023moleculardeterminantsof pages 6-8
5. dastidar2024multifacetedrolesof pages 1-2
6. dastidar2024multifacetedrolesof pages 2-5
7. dastidar2024multifacetedrolesof pages 10-11
8. dastidar2024multifacetedrolesof pages 7-9
9. dastidar2024multifacetedrolesof pages 13-15
10. https://doi.org/10.1126/science.adf4154
11. https://doi.org/10.1093/brain/awad340
12. https://doi.org/10.1101/2024.09.27.615438
13. https://doi.org/10.3389/fnint.2023.1275794
14. https://doi.org/10.1007/s12035-023-03768-z;
15. https://doi.org/10.1089/ars.2022.0124;
16. https://doi.org/10.1089/ars.2022.0124
17. https://doi.org/10.1126/science.adf4154;
18. https://doi.org/10.1093/brain/awad340;
19. https://doi.org/10.1007/s12035-023-03768-z
20. https://doi.org/10.1093/brain/awad340,
21. https://doi.org/10.1007/s12035-023-03768-z,
22. https://doi.org/10.1126/science.adf4154,
23. https://doi.org/10.1101/2024.09.27.615438,
24. https://doi.org/10.1089/ars.2022.0124,
25. https://doi.org/10.3389/fnint.2023.1275794,